Hiring Ernst & Young in the U.S. may help but won’t work without a bilateral Sino-American accord on audit documents

With listing on STAR Market, loss-making cancer-drug developer would be the first Chinese biotech to trade shares on the mainland and in Hong Kong and New York

Eleven-year-old cancer-focused Chinese biotech turned its first profit this year after three of its drugs made China’s National Reimbursement Drug List

Beijing-based BeiGene will take over commercialization of three cancer medicines from American biopharmaceutical giant in China as part of deal, and work to commercialize 20 more

Top 15 listings by Chinese firms have raised $28.7 billion so far this year, led by China Tower this week

After lackluster BeiGene IPO, analysts argue share prices will rise when more products hit market

Hong Kong IPO could raise nearly $1 billion, complementing drug developer’s current Nasdaq listing

U.S. biopharmaceutical firm plans to hold 5.9% of cancer-drug developer to market new treatments in Europe and America